Siga Technologies EV/EBIT SIGA
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 4.3×
- Jul 2026
- 8-year median
- 4.8×
- 8-year range
- 1.0× to 27.2×
- Peer median
- 4.9×
Siga Technologies has no meaningful EV/EBIT today: it made an operating loss of $11.1M over the last twelve months.
It was last meaningful in Jul 2026, at 4.3×.
On the days it had one over the last 8 years, its median was 4.8×, from 1.0× in Nov 2018 to 27.2× in Nov 2021.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.3× | 2.7× | 9.7× |
| 2025 | 3.1× | 2.7× | 6.2× |
| 2024 | 3.1× | 3.1× | 6.8× |
| 2023 | 8.4× | 2.8× | 9.1× |
| 2022 | 3.1× | 3.1× | 19.6× |
| 2021 | 21.3× | 3.8× | 27.2× |
| 2020 | 8.9× | 8.5× | 24.9× |
| 2019 | 1.2× | 1.0× | 1.6× |
| 2018 | 1.5× | 1.0× | 1.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Siga Technologies' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| SIGASiga Technologies | n/m |
| NATRNatures Sunshine Products | 5.2× |
| ARVNArvinas | n/m |
| PBYIPuma Biotechnology | 15.6× |
| IRWDIronwood Pharmaceuticals | 3.5× |
| ZVRAZevra Therapeutics | 2.9× |
| CRMDCorMedix | 2.3× |
| LFVNLifevantage | 9.6× |
| COLLCollegium Pharmaceutical | 9.4× |
| SPROSpero Therapeutics | 2.1× |
| ABUSArbutus Biopharma | 4.9× |
| Peer median | 4.9× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Siga Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.